Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Shows Positive Overall Survival Trend Versus Chemotherapy in Patients With Previously Treated Egfr-Mutated Lung Cancer
Rybrevant®(阿米伐單抗Vmjw)連化療與先前治療過的EGFR基因突變肺癌患者相比顯示出積極的總生存趨勢
Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Shows Positive Overall Survival Trend Versus Chemotherapy in Patients With Previously Treated Egfr-Mutated Lung Cancer
Rybrevant®(阿米伐單抗Vmjw)連化療與先前治療過的EGFR基因突變肺癌患者相比顯示出積極的總生存趨勢
譯文內容由第三人軟體翻譯。